| Literature DB >> 35102279 |
Ping Song1, Lucia Ruojia Wu1, Yan Helen Yan2, Jinny X Zhang2, Tianqing Chu3, Lawrence N Kwong4, Abhijit A Patel5, David Yu Zhang6.
Abstract
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the monitoring of drug resistance, and for the early detection of cancers. However, the analysis of cfDNA for clinical diagnostic applications remains challenging because of the low concentrations of cfDNA, and because cfDNA is fragmented into short lengths and is susceptible to chemical damage. Barcodes of unique molecular identifiers have been implemented to overcome the intrinsic errors of next-generation sequencing, which is the prevailing method for highly multiplexed cfDNA analysis. However, a number of methodological and pre-analytical factors limit the clinical sensitivity of the cfDNA-based detection of cancers from liquid biopsies. In this Review, we describe the state-of-the-art technologies for cfDNA analysis, with emphasis on multiplexing strategies, and discuss outstanding biological and technical challenges that, if addressed, would substantially improve cancer diagnostics and patient care.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35102279 PMCID： PMC9336539 DOI： 10.1038/s41551-021-00837-3
Source DB: PubMed Journal: Nat Biomed Eng ISSN： 2157-846X Impact factor: 29.234